Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A.
about
Immune response to vaccine adjuvants during the first year of lifeCD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammationThe ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid ANedd8 regulates inflammasome-dependent caspase-1 activation.IKKα negatively regulates ASC-dependent inflammasome activation.Type I interferon signaling contributes to the bias that Toll-like receptor 4 exhibits for signaling mediated by the adaptor protein TRIF.Caspase-1 Dependent IL-1β Secretion and Antigen-Specific T-Cell Activation by the Novel Adjuvant, PCEP.Effects of Differences in Lipid A Structure on TLR4 Pro-Inflammatory Signaling and Inflammasome Activation.Sensing and reacting to microbes through the inflammasomes.Toll-like receptor 4-interacting SPA4 peptide suppresses the NLRP3 inflammasome in response to LPS and ATP stimuliSelective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist.Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteriaComparative Transcriptome Profiles of Human Blood in Response to the Toll-like Receptor 4 Ligands Lipopolysaccharide and Monophosphoryl Lipid A.Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes.Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants.Mechanisms of action of adjuvantsTRIM32-TAX1BP1-dependent selective autophagic degradation of TRIF negatively regulates TLR3/4-mediated innate immune responses.Mitochondria-targeted drugs enhance Nlrp3 inflammasome-dependent IL-1β secretion in association with alterations in cellular redox and energy status.Naturally occurring low biological reactivity lipopolysaccharides as vaccine adjuvants.Specific features of human monocytes activation by monophosphoryl lipid A.
P2860
Q27016633-91294342-6677-4F51-BFA8-EFFD1DF9BB22Q28506984-6A3A63D7-6A53-46B8-A81D-77CC07FBDB45Q34618662-C9C19D6A-A002-4417-9288-69FD9712D870Q34701875-F509F985-963C-480C-818F-ADBEA3F95561Q34846646-B89E66C0-AC68-48C6-AD43-10DEDEE17D75Q34982165-634FC0C6-EA01-4F1D-BEC8-F360BC7AA1A2Q35695840-02AD7B43-C711-474A-8D78-2B1EEB2DB896Q35826657-7350D80C-76EE-4E4E-8B48-7B0D01B3F94DQ36029323-5E9CC380-D768-4312-B612-CE3D111139C0Q36253171-60867093-4EB3-4E37-9963-0811A67F02A6Q36322359-DE7D1D7F-D4B2-49CA-9302-7E104D9E7CCEQ36933812-2F98120E-58DE-42B2-A468-21BB94ECEE27Q37123782-38BB0A67-B067-436C-86A2-86F72630BDC9Q37560510-28452C9B-4681-4258-AAAA-34E361CC6108Q37979861-45E5FD2E-E5F2-4B7D-8011-2D903027CF40Q37981769-64B7740F-9C4F-4474-8D7F-5C1C3BFA1FE5Q38110539-E88C8EDB-0DE9-4D63-8AAE-3531D6558834Q40051350-BE1A7FF3-C45D-4B47-A571-601C52B7A63FQ42056008-80647BB8-9D51-4B84-8B0C-3EE3847452CBQ43753943-3D55572F-5CC2-4E0F-A49C-825BC7C9E5DBQ55024241-3A820891-90A7-4361-B27D-ED28EA62AA54
P2860
Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A.
@en
type
label
Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A.
@en
prefLabel
Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A.
@en
P2093
P2860
P1433
P1476
Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A.
@en
P2093
Chelsea A Embry
Gabriel Nuñez
Luigi Franchi
Thomas C Mitchell
P2860
P356
10.1126/SCISIGNAL.2001486
P577
2011-05-03T00:00:00Z